Data from Optimer Pharmaceuticals’ Prulifloxacin Phase 3 Trial in Traveler’s Diarrhea and Strain Typing Data from OPT-80 Study t
Results from three studies related to Optimer Pharmaceuticals, Inc.’s (NASDAQ:OPTR) developmental product candidates will be presented at this year’s joint meeting of the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Disease Society of America (IDSA), to be held at the Walter E. Washington Convention Center in Washington, D.C. on October 25-28, 2008.
The presentations and speakers include:
'A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Prulifloxacin as Therapy for Traveler's Diarrhea' Presenter: Herbert L. DuPont, MD
Tuesday, October 28 at 10:00am Eastern Time
Press Conference (for members of media only) in the Press Conference Room, 143C Press conference will be followed by a poster presentation which is open to all conference attendees:
Tuesday, October 28 at 12:15pm-1:15pm Eastern Time
Presentation number: L-4134a in Hall C
'Epidemic BI/NAP1 is the Dominant Strain of Clostridium difficile found in Patients in the OPT-80 vs. Vancomycin Clinical Trial in North America and the European Union' Presenter: Adam K. Cheknis
Saturday, October 25 at 12:15pm-1:15pm Eastern Time
Presentation number: K-508 in Hall C
'SAR Of 11, 12-Carbamate Macrolides/ketolides Linked With 1,4-Substituted- (1,2,3)-triazoles.' Optimer and Cempra Pharmaceuticals will be presenting collaborative data on CEM-101/OP-1068. Presenter: David Pereira Tuesday, October 28 at 11:15am-12:15pm Eastern Time
Presentation number: F1-3973 in Hall C
There will also be a symposium chaired by Dale N. Gerding, MD, Loyola University Chicago Stritch School of Medicine, Maywood, IL, which is supported by an educational grant from Optimer Pharmaceuticals.
'Clostridium difficile Infections: Current Challenges and Treatments' will address the global and epidemic nature of this potentially fatal disease.
Friday, October 24 at 6:00pm-8:00pm Eastern Time
Ballroom C of the convention center
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. OPT-80 is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic being developed for the treatment of travelers’ diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.